Bayer AG has hit the acquisition trail again, having just agreed to buy the UK's KaNDy Therapeutics Ltd., and a number of other deals are in the pipeline following a revamp of its partnering activities.
Key to the revamp is Marianne De Backer, head of pharmaceuticals business development (BD) and licensing at Bayer, who joined the German group in September 2019 from Johnson & Johnson where she spearheaded BD activities across different therapeutic areas and geographies